

A NEW LIGNAN FROM *Saururus chinensis*


Jianbin Liu,¹ Lishu Wang,^{2,3} Daqing Zhao,³
Dongyan Cheng,² Tunhai Xu,⁴ Xuefeng Zhou,⁵
Xianwen Yang,⁵ and Yonghong Liu^{5*}

UDC 547.945

Saururus chinensis (Lour.) Baill (Saururaceae) has been used in Chinese folk medicine for treatment of various diseases such as edema, jaundice, and gonorrhea, and as antipyretic, diuretic, and anti-inflammatory agents [1]. *S. chinensis* was reported to contain compounds such as lignans, including six types: dibenzylbutane lignans, monoepoxylignans (substituted tetrahydrofurans), sauchinone-type lignans, alkyl aryl ether neolignans, sesquieolignans, and dineolignans; dibenzylbutane lignans: 2'-hydroxydihydroguaiaretic acid [2], meso-dihydroguaiaretic acid [3], austrobailignan-5 [4], erythro-austrobailignan-6, (+)-saururione [5], and saururin A [6]; monoepoxylignans (substituted tetrahydrofurans): rel-(8*R*,8'*R*)-dimethyl-(7*S*,7'*R*)-bis (3,4-methylenedioxyphenyl)tetrahydrofuran, nectandrin B [5], (+)-saucermetin [7], galbacin [8], and di-*O*-methyltetrahydrofurguaiacin B [9]; alkyl aryl ether neolignans: machilin D [2] and virolin [6, 9]; sesquieolignans: saucerneols A-C [9], saucerneols D and E, (–)-saucerneol methyl ether [7], and (–)-saucerneol [10]; dineolignans: 4-*O*-demethylmanassantin A, 4-*O*-demethylmanassantin B [11], manassantins A and B [12–14], saucermetin-7 [15, 16], saucermetin-8 [17], threo,erythro-manassantin A, and erythro,erythro-manassantin A [18]; sauchinone-type lignans: sauchinone, sauchinone A, 1'-*epi*-sauchinone [8], *ent*-sauchinone [19], and sauchinone B [5].

The herbs of *S. chinensis* were purchased at the local herb-drug store and identified as *S. chinensis* with the assistance of Prof. M. L. Deng of the Department of Pharmacy, Changchun University of Chinese Medicine.

The dried herbs *S. chinensis* (5 kg) were extracted twice with aq. 70% EtOH under reflux. The extract was concentrated until the weight ratio (EtOH–dried herb) was 1:1 and left to stand at room temperature overnight; brown yellow precipitates were obtained after filtration of the solution and drying the precipitates at 55°C, yielding 105 g of residue. The residue was applied to a silica gel column and eluted by petroleum ether–EtOAc, 20:1→3:1, to get 10 fractions. The fractions were combined to give five parts (F1–F5) according to TLC check. F5 (3 g) was subjected to silica gel column chromatography using petroleum ether–EtOAc (4:1) and purified by HPLC to get saururine A (29.5 mg).



1) Clinical Laboratory Center, General Hospital of the Air Force, Beijing 100142, P. R. China; 2) Jilin Provincial Academy of Chinese Medicine Sciences, Changchun 130021, P. R. China; 3) College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, P. R. China; 4) School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, P. R. China; 5) Key Laboratory of Marine Bio-resources Sustainable Utilization, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510-301, P. R. China, fax: +86 20 84451672, e-mail: yonghongliu@scsio.ac.cn. Published in *Khimiya Prirodnykh Soedinenii*, No. 4, pp. 532–533, July–August, 2010. Original article submitted March 13, 2009.

Herein, we report the isolation of a new lignan, saururine A. Saururine A was isolated as a white powder. The molecular formula was established as C₂₃H₂₈O₇ on the basis of the HR-ESI-MS molecular ion peak at *m/z* [M + H]⁺ 417.1907 (calcd 417.1913, Δ+0.8 mmu). ¹H and ¹³C NMR data were very similar to those of schisantherin Q [20] except for the different substituent of the bisphenyl system. The ¹H NMR spectrum showed the presence of two secondary methyls (δ 1.87 (3H, d, J = 6.4 Hz, Me-18), 1.55 (3H, d, J = 6.8 Hz, Me-17), three aromatic protons (δ 7.51, 7.50, 6.53), and five methoxyls (δ 3.92, 3.88, 3.88, 3.75, 3.75). The ¹³C NMR and DEPT spectra exhibited 18 carbon atoms (including 12 aromatic ones, an oxymethine, a ketone, and two secondary methyls) for the dibenzocyclooctadiene skeleton, in addition to five methoxyl groups. The ¹H and ¹³C signal assignments were supported by COSY, HSQC, and HMBC experiments. Thus, compound was defined as 2,3,4,12,13-methoxy-6-hydroxy-8,1-dibenzocyclooctadiene, saururine A.

The main class of compounds isolated from this species is lignans, which can be divided into five types on the basis of the carbon framework: dibenzylbutane lignans, monoepoxylignans (substituted tetrahydrofurans), alkyl aryl ether neolignans, sesquieolignans, and dineolignans. To the best of our knowledge, saururine A is the first dibenzocyclooctadiene-type lignan isolated from *S. chinensis*. This suggests that the presence of dibenzocyclooctadiene lignan can be considered as a chemosystematic marker for this species. This observation might have some chemotaxonomic implications in this species.

Saururine A, white powder; ¹H NMR (500 MHz, CD₃OD, δ, ppm, J/Hz): 1.87 (3H, d, J = 6.4, Me-18), 1.55 (3H, d, J = 6.8, Me-17), 3.49 (H-6), 1.59 (H-7), 2.40 (H-8), 3.92 (3H, s, OMe), 3.88 (6H, s, OMe), 3.75 (6H, s, OMe), 7.51 (H-14), 7.50 (H-1), 6.53 (H-11); ¹³C NMR (125 MHz, CD₃OD, δ): 197.4 (C-9), 153.2 (C-12), 152.8 (C-3), 142.5 (C-2), 134.6 (C-4), 134.1 (C-13), 130.8 (C-10), 130.5 (C-5), 125.5 (C-15, C-16), 107.1 (C1, C-14), 102.8 (C-11), 80.7 (C-6), 60.9 (OMe), 56.2 (OMe, overlapped), 55.9 (OMe, overlapped), 18.3 (C-17), 17.9 (C-18), 50.8 (C-7), 31.9 (C-8); HR-ESI-MS *m/z* 417.1907 (calcd for C₂₃H₂₈O₇, 417.1913).

ACKNOWLEDGMENT

This study was supported by grants from the National Natural Science Foundation of China (No. 40706046, 30973679, and 20902094), the Knowledge Innovation Program of Chinese Academy of Science (LYQY200703, SQ200904), the National Key Basic Research Program of China (973) Project (2010CB833800), the Scientific Research Foundation for Returned Overseas Chinese Scholars, the State Education Ministry, and LMB (091002) Foundation.

REFERENCES

1. National Pharmacopoeia Committee, "Chinese Pharmacopoeia," Chemical Industrial Press, Beijing, 2005.
2. W. S. Lee, Y. I. Baek, J. R. Kim, K. H. Cho, D. E. Sok, and T. S. Jeong, *Bioorg. Med. Chem. Lett.*, **14**, 5623 (2004).
3. T. C. Moon, C. S. Seo, K. Haa, J. C. Kim, N. K. Hwang, T. G. Hong, J. H. Kim, D. H. Kim, J. K. Son, and H. W. Chang, *Arch. Pharmacol. Res.*, **31**, 606 (2008).
4. W. Fang, J. L. Ruan, and M. H. Li, *Zhong Yao Cai*, **28**, 96 (2005).
5. C. S. Seo, Y. K. Lee, Y. J. Kim, J. S. Jung, Y. Jahng, H. W. Chang, D. K. Song, and J. K. Son, *Biol. Pharm. Bull.*, **31**, 523 (2008).
6. B. T. Ahn, S. Lee, S. B. Lee, E. S. Lee, J. G. Kim, S. H. Bok, and T. S. Jeong, *J. Nat. Prod.*, **64**, 1562 (2001).
7. B. Y. Hwang, J. H. Lee, J. B. Nam, Y. S. Hong, and J. J. Lee, *Phytochemistry*, **64**, 765 (2003).
8. S. H. Sung and Y. C. Kim, *J. Nat. Prod.*, **63**, 1019 (2000).
9. S. H. Sung, M. S. Huh, and Y. C. Kim, *Chem. Pharm. Bull.*, **49**, 1192 (2001).
10. S. Y. Park, S. H. Lee, W. H. Choi, E. M. Koh, J. H. Seo, S. Y. Ryu, Y. S. Kim, D. Y. Kwon, and W. S. Koh, *Planta Med.*, **73**, 674 (2007).
11. S. H. Sung, *Fitoterapia*, **77**, 487 (2006).
12. O. E. Kwon, H. S. Lee, S. W. Lee, M. Y. Chung, K. H. Bae, M. C. Rho, and Y. K. Kim, *Arch. Pharm. Res.*, **28**, 55 (2005).

13. W. S. Lee, D. W. Lee, Y. I. Baek, S. J. An, K. H. Cho, Y. K. Choi, H. C. Kim, H. Y. Park, K. H. Bae, and T. S. Jeong, *Bioorg. Med. Chem. Lett.*, **14**, 3109 (2004).
14. M. C. Rho, O. E. Kwon, K. Kim, S. W. Lee, M. Y. Chung, Y. H. Kim, M. Hayashi, H. S. Lee, and Y. K. Kim, *Planta Med.*, **69**, 1147 (2003).
15. H. J. Park, R. G. Kim, B. R. Seo, J. Ha, B. T. Ahn, S. H. Bok, Y. S. Lee, H. J. Kim, and K. T. Lee, *Planta Med.*, **69**, 947 (2003).
16. M. Ma, J. L. Ruan, and K. V. Rao, *Chin. Trad. Herb. Drugs*, **32**, 9 (2001).
17. B. R. Seo, C. B. Yoo, H. J. Park, J. W. Choi, K. Seo, S. K. Choi, and K. T. Lee, *Biol. Pharm. Bull.*, **27**, 1594 (2004).
18. J. C. Hahm, I. K. Lee, W. K. Kang, S. U. Kim, and Y. J. Ahn, *Planta Med.*, **71**, 464 (2005).
19. L. S. Wang, D. Q. Zhao, D. Y. Cheng, and Y. H. Liu, *Heterocycles*, **75**, 1241 (2008).
20. J. S. Liu and L. Li, *Phytochemistry*, **38**, 1009 (1995).